JP2007509121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509121A5 JP2007509121A5 JP2006536175A JP2006536175A JP2007509121A5 JP 2007509121 A5 JP2007509121 A5 JP 2007509121A5 JP 2006536175 A JP2006536175 A JP 2006536175A JP 2006536175 A JP2006536175 A JP 2006536175A JP 2007509121 A5 JP2007509121 A5 JP 2007509121A5
- Authority
- JP
- Japan
- Prior art keywords
- furo
- compound according
- disease
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000006735 deficit Effects 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 241000208125 Nicotiana Species 0.000 claims 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- UZDRUJAYSVUWDI-FQEVSTJZSA-N (3r)-5'-furo[2,3-b]pyridin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1=CC=C2C(C=3C=C4C[C@]5(C6CCN(CC6)C5)OC4=NC=3)=COC2=N1 UZDRUJAYSVUWDI-FQEVSTJZSA-N 0.000 claims 1
- YGOVFMYBZIZYHQ-FQEVSTJZSA-N (3r)-5'-furo[2,3-c]pyridin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound N1=CC=C2C(C=3C=C4C[C@]5(C6CCN(CC6)C5)OC4=NC=3)=COC2=C1 YGOVFMYBZIZYHQ-FQEVSTJZSA-N 0.000 claims 1
- WIQMBWFRMTZYJN-FQEVSTJZSA-N (3r)-5'-furo[3,2-b]pyridin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1=CN=C2C(C=3C=C4C[C@]5(C6CCN(CC6)C5)OC4=NC=3)=COC2=C1 WIQMBWFRMTZYJN-FQEVSTJZSA-N 0.000 claims 1
- WPJRIWVOHGWXKG-FQEVSTJZSA-N (3r)-5'-furo[3,2-c]pyridin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1=NC=C2C(C=3C=C4C[C@]5(C6CCN(CC6)C5)OC4=NC=3)=COC2=C1 WPJRIWVOHGWXKG-FQEVSTJZSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51289303P | 2003-10-21 | 2003-10-21 | |
| US60/512,893 | 2003-10-21 | ||
| PCT/GB2004/004484 WO2005042538A1 (en) | 2003-10-21 | 2004-10-21 | Spirofuropyridine aryl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509121A JP2007509121A (ja) | 2007-04-12 |
| JP2007509121A5 true JP2007509121A5 (enExample) | 2007-11-08 |
| JP4855264B2 JP4855264B2 (ja) | 2012-01-18 |
Family
ID=34549233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536175A Expired - Fee Related JP4855264B2 (ja) | 2003-10-21 | 2004-10-21 | スピロフロピリジンアリール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7544693B2 (enExample) |
| EP (1) | EP1678183A1 (enExample) |
| JP (1) | JP4855264B2 (enExample) |
| KR (1) | KR20060094962A (enExample) |
| CN (1) | CN100494202C (enExample) |
| AU (1) | AU2004285751B2 (enExample) |
| BR (1) | BRPI0415546A (enExample) |
| CA (1) | CA2543436A1 (enExample) |
| IL (1) | IL174700A0 (enExample) |
| MX (1) | MXPA06004299A (enExample) |
| NO (1) | NO20062307L (enExample) |
| NZ (1) | NZ546413A (enExample) |
| WO (1) | WO2005042538A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005022788A1 (de) * | 2005-05-12 | 2006-11-23 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2018210229A1 (zh) * | 2017-05-18 | 2018-11-22 | 南京明德新药研发股份有限公司 | α-7尼古丁乙酰胆碱受体激动剂及应用 |
| US11440912B2 (en) | 2017-10-27 | 2022-09-13 | Fresenius Kabi Oncology Ltd | Process for the preparation of ribociclib and its salts |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| US6569865B2 (en) * | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| DK1397366T3 (da) * | 2001-06-01 | 2007-05-07 | Astrazeneca Ab | Hidtil ukendt ligander for nicotinacetylcholinreceptorer egnede i terapi |
| WO2003032897A2 (en) * | 2001-10-16 | 2003-04-24 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| EP1499618B1 (en) | 2002-04-18 | 2010-10-13 | AstraZeneca AB | Furyl compounds |
| KR20040099446A (ko) * | 2002-04-18 | 2004-11-26 | 아스트라제네카 아베 | 헤테로시클릭 화합물 |
| CN1325499C (zh) * | 2002-04-18 | 2007-07-11 | 阿斯特拉曾尼卡有限公司 | 噻吩基化合物 |
-
2004
- 2004-10-21 EP EP04768999A patent/EP1678183A1/en not_active Withdrawn
- 2004-10-21 JP JP2006536175A patent/JP4855264B2/ja not_active Expired - Fee Related
- 2004-10-21 KR KR1020067007612A patent/KR20060094962A/ko not_active Ceased
- 2004-10-21 NZ NZ546413A patent/NZ546413A/en unknown
- 2004-10-21 CA CA002543436A patent/CA2543436A1/en not_active Abandoned
- 2004-10-21 WO PCT/GB2004/004484 patent/WO2005042538A1/en not_active Ceased
- 2004-10-21 MX MXPA06004299A patent/MXPA06004299A/es active IP Right Grant
- 2004-10-21 CN CNB2004800311537A patent/CN100494202C/zh not_active Expired - Fee Related
- 2004-10-21 AU AU2004285751A patent/AU2004285751B2/en not_active Ceased
- 2004-10-21 BR BRPI0415546-7A patent/BRPI0415546A/pt not_active IP Right Cessation
- 2004-10-21 US US10/575,590 patent/US7544693B2/en not_active Expired - Fee Related
-
2006
- 2006-03-30 IL IL174700A patent/IL174700A0/en unknown
- 2006-05-22 NO NO20062307A patent/NO20062307L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527588A5 (enExample) | ||
| KR102087756B1 (ko) | 치환된 티오펜- 및 푸란-융합된 아졸로피리미딘-5-(6h)-온 화합물 | |
| TWI323733B (en) | Diazabicyclic central nervous system active agents | |
| DE69815161T2 (de) | Azindolethylaminderivate als Nikotin-acetylcholin-Rezeptor Bindung Verbindungen | |
| ES2383001T3 (es) | Compuestos de heteroarilo condensado sustituidos con azabicíclico para el tratamiento de enfermedades | |
| EP2387395B1 (en) | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer | |
| ES2392997T3 (es) | Ligandos de receptores nicotínicos de acetilcolina 101 | |
| JP2009537517A5 (enExample) | ||
| US20150158867A1 (en) | Azaadamantane derivatives and methods of use | |
| CA2491506A1 (en) | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | |
| JP2005534624A5 (enExample) | ||
| CN105294736A (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| ZA200105835B (en) | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands. | |
| CA2482311A1 (en) | Furyl compounds | |
| CA3085255A1 (en) | Eif4e-inhibiting compounds and methods | |
| JP2004532877A5 (enExample) | ||
| CN103145711A (zh) | 氮杂金刚烷酯和氨基甲酸酯衍生物及其使用方法 | |
| US20230129359A1 (en) | Muscarinic receptor 4 antagonists and methods of use | |
| US20120196890A1 (en) | 4-substituted azaadamantane derivatives and methods of use thereof | |
| JP2007509121A5 (enExample) | ||
| US9682980B2 (en) | Positive allosteric modulators of mGluR2 | |
| JP2007515479A5 (enExample) | ||
| JP2007515480A5 (enExample) | ||
| JP6420400B2 (ja) | 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物 | |
| JP2007515478A5 (enExample) |